Princess Ghida Talal: The Arab Dream for Cancer Research is Now a Movement

Princess Ghida Talal

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

100 influential women in oncology

FDA’s New “Plausible Mechanism Pathway” Marks a Major Turning Point for Individualized Therapies

FDA-OncoDaily

The Winners of CCI President's Recognition Awards 2025

CCI

20 Posts Not to Miss from COSA-IPOS 2025 World Congress

COSA-IPOS 2025 World Congress

Tanja Spanic: Insights from Alberto Costa’s Legacy in Breast Cancer Treatment

Tanja Spanic

100 Influential People in Oncology 2025 - Nominations are Open!

100 Influential People in Oncology 2025

€1 Million Broermann Medical Innovation Award Honors Pioneers of Personalized CAR T-Cell Therapy

€1 Million Broermann Medical Innovation

OncoCalendar

« All Events

  • This event has passed.

Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR

Jan 21 • 1:00 PM - 2:30 PM
AACR

Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR will be held on January 21, 2025, Virtually.

The forum will explore the new generation of patient-centric cancer clinical trials, focusing on how advancements in cancer research will reshape the clinical trial process. As more people are expected to survive and live beyond cancer, largely due to clinical trials, the conference will highlight the ongoing transformation in trial design. The emphasis will be on creating more efficient, inclusive, and patient-focused trials that prioritize patient needs and preferences. This shift will be critical in ensuring broader access to innovative treatments and improving overall patient outcomes.

The upcoming session will feature a group of esteemed experts in the field of cancer research. Jan Tomlinson from the University of California, San Francisco, will share insights from a patient advocate’s perspective on the clinical trial experience. Patricia M. LoRusso, DO, PhD (HC), FAACR, from Yale Cancer Center, will discuss innovative clinical trial designs aimed at improving efficiency and inclusivity. David A. Tuveson, MD, PhD, FAACR, from CSHL Cancer Center, will highlight the Cancer Therapeutics Initiative, which focuses on translating basic research into clinical applications. Laura van ‘t Veer, PhD, from the University of California, San Francisco, will present on the second-generation design of the I-SPY 2 trial, driving advancements in precision medicine. These experts will cover a broad range of topics, all geared toward advancing cancer clinical trials and patient care.

Register Now!

Details

Organizer